Genotypic antiretroviral drug resistance testing at low viral loads in the UK

HIV Medicine

Volumn 9, Issue 8, 2008, Pages 673-676

  Cane, Patricia A ^a   Kaye, S ^b   Smit, E ^c   Tilston, P ^d   Kirk, S ^e   Shepherd, J ^f   Hopkins, M ^g   Zhang, H ^h   Geretti, A M ⁱ  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^f ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^g ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Drug resistance testing; HIV; Viralload

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CLINICAL LABORATORY; CLINICAL PRACTICE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; UNITED KINGDOM; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; GENOTYPE; GUIDELINE ADHERENCE; HIV INFECTIONS; HIV-1; HUMANS; LABORATORIES; MEDICAL AUDIT; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; VIROLOGY;

EID: 52649155607     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00607.x     Document Type: Article

References (11)

1. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. Top HIV Med 2006; 14: 827-843.
2. Gazzard B, Bernard AJ, Boffito M et al. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 2006; 7: 487-503.
3. Kantor R, Shafer RW, Follansbee S et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004; 18: 1503-1511.
4. Greub G, Cozzi-Lepri A, Ledergerber B et al. Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002; 16: 1967-1969.
5. Mackie N, Dustan S, McClure MO, Weber JN, Clarke JR. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Meths 2004; 119: 73-78.
6. Waters L, Mandalia S, Asboe D. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/mL. AIDS 2006; 20: 778-779.
7. Mitsuya Y, Winters MA, Fessel WJ et al. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL. J Acquir Immune Defic Syndr 2006; 43: 56-59.
8. Johnson VA, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15: 119-125.
9. Shafer RW, Levee DJ, Winters MA, Richmond KL, Huang D, Merigan TC. Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. J Clin Microbiol 1997; 35: 520-522.
10. Scott P, Arnold E, Evans B et al. Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother 2004; 53: 469-473.
11. UK Collaborative Group on HIV Drug Resistance. HIV Drug Resistance in the United Kingdom: Data to End of 2005. Health Protection Report, volume 1, number 31, August 2007. London.